Trial results suggest daridorexant improves sleep and daytime functioning in insomnia patients

摘要

The dual orexin receptor antagonist daridorexant improves sleep outcomes and daytime functioning in people with insomnia disorder, results from two clinical trials have suggested. The two phase III trials, published in The Lancet Neurology (2022;212:125–129) (https://www.sciencedirect.com/science/article/abs/pii/S1474442221004361) , studied the drug in a total of 1,854 patients aged 18 years and above. The first trial randomly assigned 930 patients to receive 50mg daridorexant, 25mg daridorexant or placebo each evening for three months, while the second trial randomly assigned 924 participants to receive either 25mg daridorexant, 10mg daridorexant or placebo every evening for three months.